The gene expression profiling analysis from the GSE120721 study showed increased levels of LGALS9 in AD skin lesions compared with nonlesion AD and control (healthy) skins, which confirmed our immunohistochemistry findings. This evidence concerns the gene LGALS9 and Alzheimer disease.